CN109316486A - Albendazole ivermectin powder - Google Patents
Albendazole ivermectin powder Download PDFInfo
- Publication number
- CN109316486A CN109316486A CN201811351716.0A CN201811351716A CN109316486A CN 109316486 A CN109316486 A CN 109316486A CN 201811351716 A CN201811351716 A CN 201811351716A CN 109316486 A CN109316486 A CN 109316486A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- albendazole
- ivermectin
- montmorillonite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to albendazole ivermectin powder fields, albendazole ivermectin powder is in particular disclosed, the raw material including following parts by weight: 0.20~0.26 part of ivermectin, 10.0~10.4 parts of albendazole, 23~27 parts of anhydrous sodium sulphate, 8~12 parts of starch plus beneficial 23~27 parts of powder, 3~27 parts of montmorillonite 2,0.8~1.2 part of sodium benzoate.The present invention is used to the internal epizoa such as drive away or kill pig nematode, fluke, tapeworm, mite.
Description
Technical field
The present invention relates to albendazole ivermectin powder technical field more particularly to albendazole ivermectin powders.
Background technique
Albendazole has wide spectrum anthelmintic activity, has to nematode, tapeworm, fluke and stronger kills effect.Its mechanism of action
Be by with the intracorporal tubulin binding of worm, prevent itself and alpha-tubulin from carrying out multimerization composition micro-pipe, to influence
The cell proliferations processes such as the intracorporal mitosis of worm, albumen assembly and energetic supersession.
Ivermectin, which has internal epizoa especially insect and internal nematode, well kills effect, main to use
In gastrointestinal nematode parasites, thread lungworm and the vermin of driving away the animals such as pig.Its expelling parasite mechanism is to promote presynaptic neuron
It discharges γ-aminobutyric acid (GABA), to open the chloride channel of GABA mediation.Chloride ion stream can reduce cell membrane impedance,
The depolarising for causing postsynaptic membrane rest potential slight makes polypide relaxation paralysis so that the signal between interfering neuromuscular transmits,
Cause polypide dead or is excreted.
Existing albendazole ivermectin powder effect is poor, and insecticidal effect is bad, for this purpose, the present invention propose albendazole she
Tie up rhzomorph powder.
Summary of the invention
The purpose of the present invention is to solve disadvantages existing in the prior art, and the albendazole ivermectin proposed
Powder.
To achieve the goals above, present invention employs following technical solutions:
Albendazole ivermectin powder, the raw material including following parts by weight: 0.20~0.26 part of ivermectin, albendazole 10.0
~10.4 parts, 23~27 parts of anhydrous sodium sulphate, 8~12 parts of starch plus beneficial 23~27 parts of powder, 3~27 parts of montmorillonite 2, sodium benzoate 0.8
~1.2 parts.
Preferably, the raw material including following parts by weight: 0.21~0.25 part of ivermectin, albendazole 10.1~10.3
Part, 24~26 parts of anhydrous sodium sulphate, 9~11 parts of starch plus beneficial 24~26 parts of powder, 4~26 parts of montmorillonite 2, sodium benzoate 0.9~1.1
Part.
Preferably, the raw material including following parts by weight: 0.23 part of ivermectin, 10.2 parts of albendazole, anhydrous sodium sulphate 25
Part, 10 parts of starch plus beneficial 25 parts of powder, 5 parts of montmorillonite 2,1 part of sodium benzoate.
Preferably, the weight ratio of the ivermectin and albendazole is 23:1020.
The preparation method of albendazole ivermectin powder, includes the following steps,
S1, ivermectin and anhydrous sodium sulphate are stirred, and montmorillonite is uniformly added afterwards and is uniformly mixed again for silty, are prepared into A powder；
S2, albendazole are stirred with sodium benzoate, and starch is uniformly added afterwards and is uniformly mixed again for silty, are prepared into B powder；
Then B powder is added in A powder by equivalent gradually-increased and is stirred evenly by S3, be then added plus beneficial powder continues to be uniformly mixed
After obtain C powder；
C powder is crushed to 220~240 mesh to get albendazole ivermectin powder by S4.
Preferably, in the S4, C powder is crushed to 230 mesh to get albendazole ivermectin powder.
Albendazole ivermectin powder proposed by the present invention, for driving away or killing the bodies such as pig nematode, fluke, tapeworm, mite
Interior epizoa, albendazole have wide spectrum anthelmintic activity, have to nematode, tapeworm, fluke and stronger kill effect.It acts on machine
Reason be by with the intracorporal tubulin binding of worm, prevent itself and alpha-tubulin from carrying out multimerization composition micro-pipe, thus shadow
The cell proliferations processes such as the intracorporal mitosis of worm, albumen assembly and energetic supersession are rung, ivermectin is to internal epizoa
Especially insect and internal nematode, which have, well kills effect, is mainly used for driving away gastrointestinal nematode parasites, the lung of the animals such as pig
Nematode and vermin.Its expelling parasite mechanism is to promote presynaptic neuron release γ-aminobutyric acid (GABA), to open
The chloride channel that GABA is mediated.Chloride ion stream can reduce cell membrane impedance, cause postsynaptic membrane rest potential it is slight go to pole
Change, so that the signal between interfering neuromuscular transmits, makes polypide relaxation paralysis, cause polypide dead or be excreted.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.
Embodiment one
Albendazole ivermectin powder proposed by the present invention, the raw material including following parts by weight: 0.20 part of ivermectin, acetysalicylic acid phenobarbital reach
10.0 parts of azoles, 23 parts of anhydrous sodium sulphate, 8 parts of starch plus beneficial 23 parts of powder, 3 parts of montmorillonite 2,0.8 part of sodium benzoate.
The preparation method of albendazole ivermectin powder proposed by the present invention, includes the following steps,
S1, ivermectin and anhydrous sodium sulphate are stirred, and montmorillonite is uniformly added afterwards and is uniformly mixed again for silty, are prepared into A powder；
S2, albendazole are stirred with sodium benzoate, and starch is uniformly added afterwards and is uniformly mixed again for silty, are prepared into B powder；
Then B powder is added in A powder by equivalent gradually-increased and is stirred evenly by S3, be then added plus beneficial powder continues to be uniformly mixed
After obtain C powder；
C powder is crushed to 220 mesh to get albendazole ivermectin powder by S4.
Embodiment two
Albendazole ivermectin powder proposed by the present invention, the raw material including following parts by weight: 0.23 part of ivermectin, acetysalicylic acid phenobarbital reach
10.2 parts of azoles, 25 parts of anhydrous sodium sulphate, 10 parts of starch plus beneficial 25 parts of powder, 5 parts of montmorillonite 2,1 part of sodium benzoate.
The preparation method of albendazole ivermectin powder proposed by the present invention, includes the following steps,
S1, ivermectin and anhydrous sodium sulphate are stirred, and montmorillonite is uniformly added afterwards and is uniformly mixed again for silty, are prepared into A powder；
S2, albendazole are stirred with sodium benzoate, and starch is uniformly added afterwards and is uniformly mixed again for silty, are prepared into B powder；
Then B powder is added in A powder by equivalent gradually-increased and is stirred evenly by S3, be then added plus beneficial powder continues to be uniformly mixed
After obtain C powder；
C powder is crushed to 230 mesh to get albendazole ivermectin powder by S4.
Embodiment three
Albendazole ivermectin powder proposed by the present invention, the raw material including following parts by weight: 0.26 part of ivermectin, acetysalicylic acid phenobarbital reach
10.4 parts of azoles, 27 parts of anhydrous sodium sulphate, 12 parts of starch plus beneficial 27 parts of powder, 7 parts of montmorillonite 2,1.2 parts of sodium benzoate.
The preparation method of albendazole ivermectin powder proposed by the present invention, includes the following steps,
S1, ivermectin and anhydrous sodium sulphate are stirred, and montmorillonite is uniformly added afterwards and is uniformly mixed again for silty, are prepared into A powder；
S2, albendazole are stirred with sodium benzoate, and starch is uniformly added afterwards and is uniformly mixed again for silty, are prepared into B powder；
Then B powder is added in A powder by equivalent gradually-increased and is stirred evenly by S3, be then added plus beneficial powder continues to be uniformly mixed
After obtain C powder；
C powder is crushed to 240 mesh to get albendazole ivermectin powder by S4.
Albendazole ivermectin powder proposed by the present invention, for driving away or killing the bodies such as pig nematode, fluke, tapeworm, mite
Interior epizoa, albendazole have wide spectrum anthelmintic activity, have to nematode, tapeworm, fluke and stronger kill effect.It acts on machine
Reason be by with the intracorporal tubulin binding of worm, prevent itself and alpha-tubulin from carrying out multimerization composition micro-pipe, thus shadow
The cell proliferations processes such as the intracorporal mitosis of worm, albumen assembly and energetic supersession are rung, ivermectin is to internal epizoa
Especially insect and internal nematode, which have, well kills effect, is mainly used for driving away gastrointestinal nematode parasites, the lung of the animals such as pig
Nematode and vermin.Its expelling parasite mechanism is to promote presynaptic neuron release γ-aminobutyric acid (GABA), to open
The chloride channel that GABA is mediated.Chloride ion stream can reduce cell membrane impedance, cause postsynaptic membrane rest potential it is slight go to pole
Change, so that the signal between interfering neuromuscular transmits, makes polypide relaxation paralysis, cause polypide dead or be excreted.
The foregoing is only a preferred embodiment of the present invention, but scope of protection of the present invention is not limited thereto,
Anyone skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Inventive concept is subject to equivalent substitution or change, should be covered by the protection scope of the present invention.
Claims (6)
1. albendazole ivermectin powder, which is characterized in that the raw material including following parts by weight: ivermectin 0.20~0.26
Part, 10.0~10.4 parts of albendazole, 23~27 parts of anhydrous sodium sulphate, 8~12 parts of starch plus beneficial 23~27 parts of powder, montmorillonite 2 3~
27 parts, 0.8~1.2 part of sodium benzoate.
2. albendazole ivermectin powder according to claim 1, which is characterized in that the raw material including following parts by weight:
0.21~0.25 part of ivermectin, 10.1~10.3 parts of albendazole, 24~26 parts of anhydrous sodium sulphate, 9~11 parts of starch plus beneficial powder 24
~26 parts, 4~26 parts of montmorillonite 2,0.9~1.1 part of sodium benzoate.
3. albendazole ivermectin powder according to claim 1, which is characterized in that the raw material including following parts by weight:
0.23 part of ivermectin, 10.2 parts of albendazole, 25 parts of anhydrous sodium sulphate, 10 parts of starch plus beneficial 25 parts of powder, 5 parts of montmorillonite 2, benzene first
1 part of sour sodium.
4. albendazole ivermectin powder according to claim 1, which is characterized in that the ivermectin and albendazole
Weight ratio be 23:1020.
5. the preparation method of albendazole ivermectin powder described in any one of -4 according to claim 1, which is characterized in that packet
Include following steps,
S1, ivermectin and anhydrous sodium sulphate are stirred, and montmorillonite is uniformly added afterwards and is uniformly mixed again for silty, are prepared into A powder；
S2, albendazole are stirred with sodium benzoate, and starch is uniformly added afterwards and is uniformly mixed again for silty, are prepared into B powder；
Then B powder is added in A powder by equivalent gradually-increased and is stirred evenly by S3, be then added plus beneficial powder continues to be uniformly mixed
After obtain C powder；
C powder is crushed to 220~240 mesh to get albendazole ivermectin powder by S4.
6. the preparation method of albendazole ivermectin powder according to claim 5, which is characterized in that in the S4, by C
Powder is crushed to 230 mesh to get albendazole ivermectin powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811351716.0A CN109316486A (en) | 2018-11-14 | 2018-11-14 | Albendazole ivermectin powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811351716.0A CN109316486A (en) | 2018-11-14 | 2018-11-14 | Albendazole ivermectin powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109316486A true CN109316486A (en) | 2019-02-12 |
Family
ID=65260209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811351716.0A Pending CN109316486A (en) | 2018-11-14 | 2018-11-14 | Albendazole ivermectin powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109316486A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618492A (en) * | 2020-12-15 | 2021-04-09 | 四川乾通动物药业有限公司 | Albendazole ivermectin powder and preparation method thereof |
| CN113384528A (en) * | 2021-06-15 | 2021-09-14 | 湖南喜来高动物保健品有限公司 | Ivermectin premix and preparation method and equipment thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083348A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Albendazole/ivermectin powder for livestock |
| CN103083347A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Preparation method of albendazole/ivermectin powder for livestock |
| CN103340885A (en) * | 2013-07-18 | 2013-10-09 | 成都乾坤动物药业有限公司 | Wettable albendazole ivermectin powder |
| CN106389456A (en) * | 2016-11-16 | 2017-02-15 | 佛山市正典生物技术有限公司 | Veterinary albendazole ivermectin premixing agent and preparation method thereof |
-
2018
- 2018-11-14 CN CN201811351716.0A patent/CN109316486A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083348A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Albendazole/ivermectin powder for livestock |
| CN103083347A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Preparation method of albendazole/ivermectin powder for livestock |
| CN103340885A (en) * | 2013-07-18 | 2013-10-09 | 成都乾坤动物药业有限公司 | Wettable albendazole ivermectin powder |
| CN106389456A (en) * | 2016-11-16 | 2017-02-15 | 佛山市正典生物技术有限公司 | Veterinary albendazole ivermectin premixing agent and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈剑 等主编: "《畜禽养殖基础》", 31 July 2013, 苏州大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618492A (en) * | 2020-12-15 | 2021-04-09 | 四川乾通动物药业有限公司 | Albendazole ivermectin powder and preparation method thereof |
| CN113384528A (en) * | 2021-06-15 | 2021-09-14 | 湖南喜来高动物保健品有限公司 | Ivermectin premix and preparation method and equipment thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109316486A (en) | Albendazole ivermectin powder | |
| DE2821199A1 (en) | METHOD FOR PRODUCING IODOPHORIC COMPOUNDS AND FOR STABILIZING PHARMACEUTICAL COMPOSITIONS CONTAINING IODOPHOR | |
| WO2019052047A1 (en) | Biopesticide preparation synergistic composition for preventing and controlling solenopsis invicta | |
| CN103749568A (en) | Manufacturing method for biological pesticide | |
| CN109090152A (en) | A kind of composition and preparation method thereof for environment disinfected | |
| CN103250731A (en) | Insecticide sterilization compound agent containing hymexazol | |
| CN102763681B (en) | Granula containing clothianidin | |
| CN101755776B (en) | Pesticidal composition containing cartap and flubendiamide | |
| CN101755814A (en) | Pesticidal composition containing thiamethoxam and flubendiamide | |
| CN103858923A (en) | Insecticidal composition containing imidacloprid and lambda-cyhalothrin, and application thereof | |
| CN105315075A (en) | Fertilizer capable of controlling underground crop pests | |
| DE1812005A1 (en) | omega-cyanoalkylcarbamyl-benzimidazoles | |
| CN101313678A (en) | Method for preparing cartap and imidacloprid combined water dispersible powder | |
| CN113207901A (en) | Application of acidic electrolyzed water mixed with pesticide for sterilizing and killing insects | |
| DE1966957B2 (en) | GERANYL HALOGENIDE EPOXIDES AND PROCESS FOR THEIR PRODUCTION | |
| Turner | Notes on rotenone as an insecticide | |
| Misumi et al. | Synergistic and suffocative effects of fumigation with a lower-concentration phosphine and sulfuryl fluoride gas mixture on mortality of Sitophilus species (Coleoptera: Dryophthoridae), a stored-product pest. Part 2: susceptibility test on Sitophilus zeamais for fumigation with a gas mixture, and verification test of a sequential fumigation with two fumigants | |
| DE1620095A1 (en) | Substituted rhodanepyrroles | |
| CN101313679A (en) | Method for preparing thiocyclam and imidacloprid combined water dispersible powder | |
| CN103843811B (en) | A kind of granule preventing and treating sugarcane moth borer | |
| CN107683854A (en) | A kind of nematicide of containing fluopyram and methyl jasmonate | |
| DE1962408C3 (en) | Phenyl-N-methyl-carbamates, their manufacture and their use as pesticides | |
| DE2343526A1 (en) | NEW IMIDE | |
| AT515551B1 (en) | Process for the preparation of a plant protection agent bactericidal on the bacterium Erwinia amylovora | |
| DE2129524C3 (en) | Fungicidal agents based on phenylhydrazono-imid azolenine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |
|
| RJ01 | Rejection of invention patent application after publication |